Clinical Trial Update: Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating MorphoTEP with fluorodeoxyglucose (FDG) in patients with severe sepsis of unspecified etiology; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• FDG (fluorodeoxyglucose)
• MorphoTEP

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Severe Sepsis | Phase 3 | Status: UNKNOWN